钙通道阻滞剂(CCB)已经成为最广泛使用的降压药物,并可以很好地与其他各类降压药物联合应用。二氢吡啶类CCB与血管紧张素转换酶(ACE)抑制剂或血管紧张素受体拮抗剂(ARB)的联合在多项大型临床研究中显示出优越性。氨氯地平和拉西地平等第三代CCB半衰期更长、副反应更少、抗动脉粥样硬化等心血管保护作用证据更多,特别适合于老年单纯收缩期高血压、伴冠心病或颈动脉粥样硬化的高血压患者。 Calcium Channel Blockers (CCBs) have become the most widely used antihypertensive drugs and are well suited for use with a variety of other antihypertensive drugs. The combination of dihydropyridine CCB with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) has shown superiority in a number of large clinical studies. Third-generation amlodipine and lacidipine Third-generation CCB has longer half-life, fewer side effects and more evidence of cardiovascular protection such as atherosclerosis and is particularly suitable for isolated systolic hypertension in the elderly with coronary heart disease or neck Atherosclerosis in hypertensive patients.